Drugs / [18F]GTP1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02640092 | Dec 2015 → Jun 2019 | Alzheimer disease | Genentech, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-07-19 | Genentech, Inc. | Results Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC) gene.com ↗
Baseline Tau Burden Measured by [18F]GTP1 Imaging is Associated with Subsequent Cognitive Decline in Prodromal to Mild Alzheimer’s Disease |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-19 | Genentech, Inc. | Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC) gene.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]GTP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02640092 ↗ |
| Modality | Diagnostic / imaging agent | “tau positron-emission tomography (PET) radioligand” NCT02640092 ↗ |
| Route | Intravenous | “intravenous (IV) administration” NCT02640092 ↗ |